Dr. Bekaii-Saab on the Use of Regorafenib in Patients With mCRC
In Partnership With:
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).
There are 2 studies that have helped clinicians better understand the role of regorafenib in the treatment landscape, says Bekaii-Saab. CONCUR looked at regorafenib and TARA examined the use of TAS-102 (Lonsurf). Both studies had very similar designs as RECOURSE and CORRECT, but in Asian-only populations. Those studies examined patients with less exposure to pre-biologics as a result of lower accessibility.
In CONCUR and CORRECT, the delta value was much wider for regorafenib versus no treatment. On the other hand, in TARA, earlier use of TAS-102 did not seem to change the delta value as much as in RECOURSE.
This could be a hint that moving regorafenib up or not waiting until the end of the line to administer the agent may be more beneficial to patients, says Bekaii-Saab.
